Subscribe to FDA Diabetes Monitor
FDA’s Diabetes Monitor delivers e-mail updates on safety and regulatory issues related to diabetes, including product approvals, safety warnings, notices of upcoming public meetings, and notices about proposed regulatory guidances.
An estimated 29.1 million (21.0 million diagnosed and 8.1 million undiagnosed) people in the U.S. — approximately 9.3% of the population — have diabetes. An estimated 86 million people in the U.S. (1 out of 3 adults) have prediabetes and 9 out of 10 people in the U.S. do not know they have prediabetes.With the incidence of diabetes skyrocketing, it is important that the FDA do what we can to inform patients and the health professionals. FDA is committed to getting accurate, science-based information in the hands of people with diabetes and the people who provide medical care - so they can recommend and use foods, medicines, and devices to maintain and improve patient health.
What’s new in Diabetes?
FDA-Patient Dialogue on Unmet Needs in Diabetes Meeting was held on Monday, November 3, 2014. FDA hosted a discussion with Type 1 and Type 2 diabetes communities to provide FDA with real-world perspectives as the agency deliberates complex policies that affect the safety and effectiveness of marketed products on which people with diabetes depend.
Diabetes Live Chat. On March 31, 2014, discussion was held on the FDA’s new proposed guidelines and what standards blood glucose meters should have to meet before the FDA clears them for sale. View our recent LiveChat with Bennett Dunlap creator of StripSafety.com and FDA's Courtney Lias Ph.D, Director of Chemistry and Toxicology Devices.
FDA Drug Safety Podcast: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
On May 15, 2015, FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. We are continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Listen to the Podcast